title: Adrenal cancer in 2013: Time to individualize treatment for adrenocortical cancer?
abstract: 2013 was a good year for adrenocortical cancer, as the new knowledge gained holds great promise for patients. Advances were made in genetics, epigenetics, the advent of related technological and bioinformatic tools, and the feasibility of massive screening of people and samples.
authors.affiliation: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), CRC Room 1-3330, East Laboratories, Building 10-CRC, 10 Center Drive, SEGEN/PDEGEN, NICHD, NIH, Bethesda, MD 20892, USA.
authors.forename: Constantine A
authors.initials: CA
authors.lastname: Stratakis
mesh_terms: D000306:Adrenal Cortex Neoplasms / Q000235:genetics / Q000628:therapy*; D055088:Early Detection of Cancer; D057890:Epigenomics; D006801:Humans; D057285:Precision Medicine / Q000639:trends*; D051176:beta Catenin / Q000037:antagonists & inhibitors
chemical_list: D051176:beta Catenin